Title
Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Date Issued
01 June 2019
Access level
metadata only access
Resource Type
review
Author(s)
Klochkov S.G.
Neganova M.E.
Yarla N.S.
Parvathaneni M.
Sharma B.
Tarasov V.V.
Bachurin S.O.
Ashraf G.M.
Aliev G.
Pontificia Universidad Javeriana
Publisher(s)
Academic Press
Abstract
Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.
Start page
128
End page
134
Volume
56
Language
English
OCDE Knowledge area
Oncología
Farmacología, Farmacia
Scopus EID
2-s2.0-85035094841
PubMed ID
Source
Seminars in Cancer Biology
ISSN of the container
1044579X
Sponsor(s)
Authors are grateful for the financial support according to grant № 17-73-10461 of Russian Science Foundation and the facilities of the “Center of Collective Use” of IPAC RAS, Russia.
Sources of information:
Directorio de Producción Científica
Scopus